Cellebrite DI (CLBT) to Release Earnings on Thursday

Key Points

• Cellebrite DI is set to release its Q2 2025 earnings on August 14th, with analysts expecting earnings of $0.11 per share and revenue of $112.33 million.
• The company's previous earnings report revealed a positive return on equity of 35.36%, despite a negative net margin of 46.34%.
• Cellebrite DI currently has a consensus rating of "Moderate Buy" with a target price of $22.43, influenced by recent downgrades and price adjustments from various brokerages.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect Cellebrite DI to post earnings of $0.11 per share and revenue of $112.33 million for the quarter. Cellebrite DI has set its Q2 2025 guidance at EPS and its FY 2025 guidance at EPS.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.09 by $0.01. The business had revenue of $107.55 million for the quarter, compared to analysts' expectations of $109.36 million. Cellebrite DI had a positive return on equity of 35.36% and a negative net margin of 46.34%. The firm's revenue was up 20.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.08 earnings per share. On average, analysts expect Cellebrite DI to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cellebrite DI Stock Performance

Cellebrite DI stock opened at $13.86 on Thursday. The stock has a market capitalization of $3.32 billion, a price-to-earnings ratio of -14.44, a PEG ratio of 2.75 and a beta of 1.27. Cellebrite DI has a 52-week low of $12.63 and a 52-week high of $26.30. The stock's 50 day moving average price is $15.31 and its two-hundred day moving average price is $18.26.

Institutional Investors Weigh In On Cellebrite DI

An institutional investor recently raised its position in Cellebrite DI stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 16.8% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 173,013 shares of the company's stock after purchasing an additional 24,881 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 0.07% of Cellebrite DI worth $3,362,000 as of its most recent filing with the Securities & Exchange Commission. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on CLBT. Wall Street Zen lowered Cellebrite DI from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Needham & Company LLC reissued a "buy" rating and issued a $24.00 price target on shares of Cellebrite DI in a research report on Friday, June 6th. Finally, JPMorgan Chase & Co. lowered their price target on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, May 12th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $22.43.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.